Sally Baron-Hay

7PUBLICATIONS
56CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Obstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 08, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

|Nov 05, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound

|Dec 09, 2024
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Nadia Harbeck, Eva Ciruelos, Guy Jerusalem

|Sep 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Nadia Harbeck, Eva Ciruelos, Guy Jerusalem

|Apr 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez

|Jan 08, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Deborah Smith, Kristy P Robledo, Sonia Yip

Pageof 2

Frequent Collaborators

2 joint publications

Roisin M Connolly

2 joint publications

U G Imalki U Kariyawasam

2 joint publications

Nancy U Lin

2 joint publications

Giampaolo Bianchini